Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-02-20

Schrödinger, Inc.

Schrödinger develops computational molecular modeling software for drug discovery and materials science and also earns revenue from drug-discovery collaborations and internal programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Re-rating hinges on becoming the trusted discovery runtime

A software-led pivot can turn automated molecular discovery into metered, governed throughput, supporting faster growth and a higher multiple. The near-term catalyst is guidance clarity on renewals/scale-ups and cash discipline.

Analysis

Thesis

As AI makes “molecular cognition” cheap, SDGR can win by becoming the audited execution layer for discovery (API-first + enterprise controls), shifting value capture from seats to metered campaigns while keeping pipeline upside mostly partner-funded—driving a software-led re-rate by 2031.

Last Economy Alignment

Cheaper compute increases ROI of in‑silico discovery, and SDGR’s control points (workflow integration + enterprise licensing/governance) can stay valuable even as models commoditize; the main risk is pharma in-sourcing and agent layers abstracting the tools.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

5.8x (from 5 most recent analyses)

Reasoning

SDGR is priced like a mixed-quality hybrid (software + lumpy drug discovery economics) with a near-term focus on renewals/scale-ups. The non-linear upside is less “new science” and more packaging + control: make the Python/API runtime the default execution surface for automated discovery, sell enterprise governance (policy, reproducibility, provenance), and expand wallet share via deeper LiveDesign embedding. If SDGR executes this shift while keeping internal therapeutics spend disciplined (partnering/optioning), investors can underwrite both steadier software growth and less runway risk—supporting a higher forward revenue multiple by 2031.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The binding risk is distribution timing: pharma procurement and platform standardization decisions can delay renewals/scale-ups, making growth lumpy. Strategically, SDGR must prevent “software-to-zero” dynamics by shifting value capture toward metered runtime + governed, reproducible outputs (agents can orchestrate, but must execute through SDGR to be trusted). Financially, sustained operating losses create dilution/runway sensitivity if software growth does not re-accelerate or if internal pipeline spend re-expands.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Company reaffirmed the Q4/full-year 2025 results date (Feb 25, 2026), setting a near-term two-sided repricing point.
Trading into Feb-2026 remained near the 52-week low, suggesting expectations are already conservative heading into guidance.
Product messaging increasingly emphasizes AI assistants and automation surfaces, reinforcing the API-first/agent-ready direction.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.51

They control an embedded workflow layer and an API surface that automated “lab agents” can run through, so value can shift from human clicks to governed execution. The risk is big pharmas building internal stacks and treating the tools as interchangeable unless SDGR sells trust (reproducibility, policy, provenance) as the premium feature.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$24.33

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research